

---

**THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION**

---

If you are in any doubt as to any aspect of this Supplemental Circular or as to the action to be taken, you should consult your securities dealer or other registered institution in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited\*** (廣州白雲山醫藥集團股份有限公司), you should at once hand this Supplemental circular accompanying with the Second Form of Proxy to the purchaser(s) or transferee(s) or to the bank or other agent through whom the sale or transfer was effected for transmission to the purchaser(s) or transferee(s).

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this Supplemental Circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Supplemental Circular.

---



廣州白雲山醫藥集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

**SUPPLEMENTAL CIRCULAR TO THE CIRCULAR TO SHAREHOLDERS  
DATED 11 MAY 2019  
PROPOSED ELECTION OF DIRECTOR  
AND  
SUPPLEMENTAL NOTICE OF THE AGM**

---

Capitalised terms used in this cover page have the same meanings as those defined in this Supplemental Circular.

This Supplemental Circular should be read in conjunction with the circular of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited\* (廣州白雲山醫藥集團股份有限公司) (the “Company”) dated 11 May 2019 in relation to, among other things, the AGM of the Company to be held at the Conference Room of the Company, 45 Sha Mian North Street, Liwan District, Guangzhou City, Guangdong Province, the PRC on Friday, 28 June 2019 at 10 a.m. (the “First Circular”).

A notice convening the AGM was set out in the First Circular. A Supplemental Notice of the AGM dated 11 June 2019 is set out on pages 8 to 10 of this Supplemental Circular.

An additional resolution for the proposed election of Director will be proposed at the AGM, details of which are set out in this Supplemental Circular. The Second Form of Proxy for the use at the AGM which contains the additional resolution to be proposed at the AGM is enclosed herewith. The Second Form of Proxy enclosed herewith shall supersede the First Form of Proxy enclosed in the First Circular. Whether or not you intend to attend the AGM, please complete and return the Second Form of Proxy to the office of the Company’s H Share Registrar, Hong Kong Registrars Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong (for holders of H Shares) in accordance with the instructions printed thereon as soon as possible and in any event not less than 24 hours before the time appointed for the AGM or any adjournment thereof. Completion and return of the Second Form of Proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish and in such event, the Second Form of Proxy shall be deemed to have been revoked.

12 June 2019

---

## CONTENTS

---

	<i>Page</i>
<b>Definitions</b> . . . . .	1
<b>Letter from the Board</b> . . . . .	3
<b>Appendix I – Information on Mr. Zhang Chunbo</b> . . . . .	6
<b>Supplemental Notice of the AGM</b> . . . . .	8

---

## DEFINITIONS

---

*In this Supplemental Circular, unless the context requires otherwise, the following expressions have the following meanings:*

“A Shares”	RMB-denominated domestic shares in the share capital of the Company with a nominal value of RMB1.00 each and are listed on Shanghai Stock Exchange
“AGM”	the annual general meeting of the Company for year 2018 to be held on Friday, 28 June 2019 at 10:00 a.m., including any adjournment thereof
“Articles of Association”	the articles of association of the Company
“Board”	the board of Directors
“Company”	Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited* (廣州白雲山醫藥集團股份有限公司), a joint stock company with limited liability established in the PRC, whose H Shares and A Shares are listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange respectively
“controlling shareholder”	has the meaning given to it under the Hong Kong Listing Rules
“Director”	a director of the Company
“First Circular”	the circular of the Company dated 11 May 2019
“First Form of Proxy”	the form of proxy for the AGM accompanying the First Circular
“First Notice”	the notice of the AGM dated 10 May 2019 set out in the First Circular
“GPHL”	Guangzhou Pharmaceutical Holdings Limited* (廣州醫藥集團有限公司), a state-owned enterprise established by, and under the administration of, the Guangzhou SASAC. It is the controlling shareholder of the Company which held approximately 45.04% of the issued shares of the Company as at the LPD
“Group”	the Company and its subsidiaries
“Guangzhou SASAC”	the Guangzhou Municipal People’s Government State-owned Assets Supervision and Administration Commission* (中國廣州市人民政府國有資產監督管理委員會) of the PRC

---

## DEFINITIONS

---

“H Shares”	HKD-denominated foreign shares in the share capital of the Company with a nominal value of RMB1.00 each and are listed on the Hong Kong Stock Exchange
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited
“LPD”	6 June 2019, being the latest practicable date prior to the printing of this Supplemental Circular for the purpose of ascertaining certain information contained in this Supplemental Circular
“Hong Kong Listing Rules”	Rules Governing the Listing of Securities on the Hong Kong Stock Exchange
“PRC”	the People’s Republic of China which, for the purposes of this Supplemental Circular only, excludes Hong Kong, the Macau Special Administrative Region and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“Second Form of Proxy”	the form of proxy accompanying this Supplemental Circular
“SFO”	Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)
“Shareholder”	a holder of the A Shares and/or H Shares
“Supplemental Circular”	this supplemental circular of the Company dated 12 June 2019
“Supplemental Notice”	the supplemental notice convening the AGM, as set out on pages 8 to 10 of this Supplemental Circular
“%”	per cent

---

## LETTER FROM THE BOARD

---



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

*Executive Directors:*

Mr. Li Chuyuan  
Ms. Cheng Ning  
Ms. Liu Juyan  
Mr. Ni Yidong  
Mr. Li Hong  
Mr. Wu Changhai

*Registered office and principal place  
of business:*

45 Sha Mian North Street  
Liwan District  
Guangzhou City, Guangdong Province  
The PRC

*Independent non-executive Directors:*

Mr. Chu Xiaoping  
Mr. Jiang Wenqi  
Mr. Wong Hin Wing  
Ms. Wang Weihong

*Principal place of business in Hong Kong:*

Room 2005, 20th Floor  
Tower Two Lippo Centre  
89 Queensway  
Hong Kong

12 June 2019

*To the Shareholders*

Dear Sir or Madam:

### **PROPOSED ELECTION OF DIRECTOR AND SUPPLEMENTAL NOTICE OF THE AGM**

#### **1. INTRODUCTION**

This Supplemental Circular should be read in conjunction with the First Circular which contains, among other things, matters to be transacted at the AGM. The purpose of this Supplemental Circular is to provide you with the information of the additional resolution to be proposed at the AGM regarding the proposed election of Director at the AGM and to provide Shareholders with the Supplemental Notice and the Second Form of Proxy.

#### **2. PROPOSED ELECTION OF DIRECTOR**

In accordance with the Articles of Association and the rules of procedures of the Board of Directors, the Board shall consist of eleven Directors. Since Mr. Chen Mao resigned as an executive Director on 31 May 2019, the number of current Directors of the seventh session of the Board was ten. In order to ensure the smooth implementation of the work of the Board, at the meeting of the Board held on 3 June 2019, the Board resolved to elect Mr. Zhang Chunbo (張春波), the current deputy general manager of the Company, as an executive Director subject to the approval of the Shareholders at the AGM.

---

## LETTER FROM THE BOARD

---

The nomination and remuneration committee of the Company (“**Nomination and Remuneration Committee**”) makes recommendations to the Board in respect of identifying qualified persons to replace Mr. Chen Mao in accordance with its terms of reference and the Company’s nomination policy.

In making the recommendation to the Board for the proposed election of Mr. Zhang Chunbo, the Nomination and Remuneration Committee has made reference to objective criteria including but not limited to educational background, industry experience, technical and professional skills, qualifications, knowledge and length of service. After taking into account the recommendation of the Nomination and Remuneration Committee, the Board resolved at its meeting held on 3 June 2019 to elect Mr. Zhang Chunbo as an executive Director of the Company. In this connection, an ordinary resolution to be taken by way of cumulative poll will be proposed at the AGM for the Shareholders to consider and, if thought fit, approve the election of Mr. Zhang Chunbo as an executive Director. Particulars of Mr. Zhang Chunbo as at the LPD and further information required to be disclosed pursuant to Rule 13.51(2) of the Hong Kong Listing Rules are set out in Appendix I to this Supplemental Circular.

### 3. AGM

The AGM will be held as originally scheduled at the Conference Room of the Company, 45 Sha Mian North Street, Liwan District, Guangzhou City, Guangdong Province, the PRC on Friday, 28 June 2019 at 10:00 a.m. The Supplemental Notice is set out on pages 8 to 10 to this Supplemental Circular. The Supplemental Notice should be read in conjunction with the First Notice.

The First Form of Proxy was despatched to the Shareholders on Saturday, 11 May 2019 and has also been published on the website of the Hong Kong Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)). Since the First Form of Proxy does not contain the resolution in relation to the proposed election of Director as set out in the Supplemental Notice, the Company has prepared the Second Form of Proxy for despatch together with this Supplemental Circular. The additional resolution is set out in the Supplemental Notice set out on page 8 of this Supplemental Circular.

Whether or not you intend to attend the AGM, please complete and return the Second Form of Proxy to the office of the Company’s H Share Registrar, Hong Kong Registrars Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong (for holders of H Shares) in accordance with the instructions printed thereon as soon as possible and in any event not less than 24 hours before the time appointed for the AGM or any adjournment thereof. Completion and return of the Second Form of Proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish and in such event, the Second Form of Proxy shall be deemed to have been revoked.

All the votes of the Shareholders at the AGM will be taken by poll.

Holders of H Share(s) who have lodged the First Form of Proxy should note that:

- (1) If the Second Form of Proxy is lodged with the office of the Company’s H Share Registrar 24 hours prior to the time designated for convening the AGM (the “Closing Time”), the Second Form of Proxy will revoke and supersede the First Form of Proxy previously lodged by him/

---

## LETTER FROM THE BOARD

---

her. The Second Form of Proxy will be treated as a valid form of proxy lodged by the holder of H Share(s) if correctly completed and signed and returned in accordance with the instructions printed thereon.

- (2) If no Second Form of Proxy is lodged with the office of the Company's H Share registrar as at the Closing Time, the First Form of Proxy will be treated as a valid form of proxy lodged by the holder of H Share(s) if correctly completed. The proxy so appointed by the holder of H Share(s) will be entitled to vote at his/her discretion or to abstain from voting on any resolution properly put to the AGM including the resolution in relation to the proposed election of Director as set out in the Supplemental Notice.

Shareholders are reminded that completion and return of the First Form of Proxy and/or the Second Form of Proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish.

#### **4. RECOMMENDATIONS AND OTHER INFORMATION**

The Board received the "Letter in relation to the Submission of an Interim Proposal to the Annual General Meeting of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited for year 2018" submitted by GPL, the controlling shareholder of the Company, pursuant to which a request was made to submit the interim proposal in relation to the proposed election of Mr. Zhang Chunbo as a Director to the AGM for consideration and approval. The Board considers that the proposed election of Mr. Zhang Chunbo as a Director is in the interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend the Shareholders to vote in favour of the proposed resolutions.

Yours faithfully

By Order of the Board

**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

## 1. BIOGRAPHICAL DETAILS

**Mr. Zhang Chunbo**, aged 42, holds a bachelor degree and a master degree of EMBA, and is a druggist. Mr. Zhang graduated from the China Pharmaceutical University in July 2000 and began his career in the same year. In December 2010, he obtained a master degree of EMBA from the Lingnan (University) College of the Sun Yat-Sen University. He had served as the vice manager of the second zone, the assistant to the manager of sales department, the vice general manager of operation department, the manager of sales department, the vice director of marketing department of Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (廣州白雲山和記黃埔中藥有限公司), the vice general manager, the vice general manager (standing), general manager and chairman of Guangzhou Baiyunshan Zhong Yi Pharmaceutical Company Limited (廣州白雲山中一藥業有限公司), general manager and chairman of Guangzhou Baiyunshan Qi Xing Pharmaceutical Co., Ltd. (廣州白雲山奇星藥業有限公司). Mr. Zhang has been the vice general manager of the Company since 12 January 2015, and is currently a member of the party committee of the Company, the chairperson of each of Guangzhou Baiyunshan Zhong Yi Pharmaceutical Company Limited and Guangzhou Baiyunshan Qi Xing Pharmaceutical Co., Ltd. Mr. Zhang has extensive experience in corporate management and marketing.

## 2. TERM OF OFFICE

If elected, the term of office of Mr. Zhang Chunbo as a member of the seventh session of the Board shall commence from the date on which he is elected at general meeting up to the date on which the members of the new session of the Board are elected. On this basis, it is expected that the term of office of Mr. Zhang as a member of the seventh session of the Board will be approximately one year. The Company will enter into a service contract with Mr. Zhang if he is elected as a Director at the AGM.

## 3. REMUNERATION

If elected at the AGM, the remuneration expected to be paid by the Company to Mr. Zhang Chunbo in 2019 will not be more than RMB1,700,000 (including tax) and will be adjusted in accordance with the “Measures in relation to the remuneration for, and performance assessment on, the senior management of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited”.

## 4. INTERESTS IN THE SHARES OF THE COMPANY WITHIN THE MEANING OF PART XV OF THE SFO

Set out below are the interests of Mr. Zhang Chunbo in the shares of the Company as at the LPD:

Capacity	Number of A Shares under the Employee Stock Ownership Scheme (2015)	Approximate percentage in the issued A Shares of the Company	Approximate percentage in the entire issued share capital of the Company
Beneficial owner	10,000	0.0007	0.0006



Save as disclosed above, neither Mr. Zhang Chunbo nor his associates had any interest in the shares of the Company within the meaning of Part XV of the SFO. The interests of Mr. Zhang Chunbo in the A Shares as disclosed in the above are held by the asset manager of the Employee Stock Ownership Scheme (2015) for the benefits of Mr. Zhang Chunbo. Details of the Employee Stock Ownership Scheme (2015) were set out in the Placing Circular and the circular of the Company dated 19 May 2015, respectively.

**5. NO OTHER INFORMATION REQUIRED TO BE DISCLOSED**

As at the LPD and save as disclosed above, Mr. Zhang Chunbo:

- (a) did not have any relationship with any other Directors, supervisors, senior management or substantial or controlling shareholders of the Company;
- (b) did not have or was not deemed to have any interest in the shares of the Company within the meaning of Part XV of the SFO;
- (c) did not hold any directorship in the last three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas;
- (d) did not hold any position in the Company or other members of the Group; and
- (e) had no other matters that needed to be brought to the attention of the Shareholders and there was no information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Hong Kong Listing Rules.

---

## SUPPLEMENTAL NOTICE OF THE AGM

---



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

### SUPPLEMENTAL NOTICE OF THE 2018 ANNUAL GENERAL MEETING

Reference is made to the notice (the “**First Notice**”) of the 2018 annual general meeting (the “**AGM**”) of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) dated 10 May 2019, the circular dated 11 May 2019 (the “**First Circular**”), regarding, among other things, (1) the proposed amendments to the Articles of Association; (2) proposed cash management of part of the temporary idle fund raising proceeds; (3) proposed cash management of part of the temporary idle internal funds; (4) proposed addition of a new entity which may use part of the placing proceeds; (5) proposed grant of general mandate to issue shares; and (6) the AGM notice, and the clarification announcement on notice of the 2018 annual general meeting and circular dated 15 May 2019, which set out the time and place of the AGM and contain the relevant resolutions to be proposed to the Shareholders at the AGM for their consideration. Unless otherwise indicated, capitalised terms used herein have the same meanings as those defined in the supplemental circular of the Company dated 12 June 2019 (the “**Supplemental Circular**”).

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the AGM will be held as originally scheduled at the Conference Room of the Company, 45 Sha Mian North Street, Liwan District, Guangzhou City, Guangdong Province, the PRC on Friday, 28 June 2019 at 10:00 a.m., for the purpose of considering the following additional resolution, together with the other resolutions set out in the First Notice:

(III) Election of a member of the seventh session of the Board by way of cumulative poll:

22. Resolution on the election of Mr. Zhang Chunbo as an executive director of the seventh session of the Board of the Company and the emoluments to be paid to him for year 2019.

The Board of  
**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 11 June 2019

*Notes:*

1. All times stated in this supplemental notice refer to Hong Kong time.
2. Application of cumulative voting method in the election of director

In accordance with the Articles of Association, the Company will adopt the cumulative voting method to voting and calculation of the voting results. As there is only one director to be elected, the number of votes that you are entitled to is equal to the total number of shares that you hold. You may cast all the votes that you are entitled to or part of them. If the votes that you cast are less than what you are entitled to, you will be deemed to have abstained from voting in respect of the difference between the number of votes that you cast and the votes that you are entitled to cast. The

---

## SUPPLEMENTAL NOTICE OF THE AGM

---

example set out below explains the operation of the cumulative voting method. If you hold 1,000,000 shares of the Company and the number of director to be elected is one, you will have 1,000,000 votes (1,000,000 shares x 1 = 1,000,000 votes) in respect of resolution No. 22. You may cast all 1,000,000 votes or only part of them and cast your votes as described below: (1) you may cast all your 1,000,000 votes or any part of them on either “for” or “against”. Should you cast a total of less than 1,000,000 votes, you will be deemed to have abstained from voting in respect of the difference; or (2) you may cast all your 1,000,000 votes or such number of votes below 1,000,000 and in each case allocate such number of votes as you wish on “for” and “against” simultaneously, and should you cast a total of less than 1,000,000 votes, you will be deemed to have abstained from voting in respect of the difference. Resolution No. 22 will be considered as having been passed if more than half of the voting rights (simple majority without cumulative counting) were cast for it by the shareholders (or their proxies) attending the AGM.

3. This supplemental notice should be read in conjunction with the First Notice, the First Circular and the Supplemental Circular.
4. Save for the inclusion of the newly proposed resolution, there are no other changes to the resolutions set out in the First Notice. Please refer to the First Notice and the First Circular for details of other resolutions to be proposed at the AGM, closure of register of members, eligibility of the AGM, registration procedures for attending the AGM, the voting arrangements, the poll procedure and other relevant matters.
5. Form of Proxy

Since the First Form of Proxy does not contain the additional resolution as set out in this supplemental notice, the Second Form of Proxy has been prepared and is enclosed with this supplemental notice.

- (i) Holders of domestic shares (A shares) and overseas listed foreign shares (H shares) whose names appear on the register of members of the Company after the end of the trading hours on 28 May 2019 (Tuesday) (including those holders of H shares who have submitted verified application documents for the transfer of shares on or before 28 May 2019 (Tuesday)) are entitled to attend the AGM. The register of members of the Company will be closed from 29 May 2019 (Wednesday) to 28 June 2019 (Friday) (both days inclusive) during which no transfer of H shares will be effected. In order to determine who are entitled to attend the AGM, all share transfer documents of H shares together with the relevant share certificates must be lodged with the share registrar of the Company in Hong Kong, namely Hong Kong Registrars Limited, at Shops 1712-1716, 17/F, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong, for share transfer registration no later than 4:00 p.m. on 28 May 2019 (Tuesday).
- (ii) Any shareholder entitled to attend and vote at the AGM is entitled to appoint one or more proxies (whether or not he/she is a shareholder) to attend and vote at the meeting on his/her behalf. If any shareholder appoints more than one proxy, the proxies can only vote by poll. To be valid, the proxy form and the notarially certified power of attorney and/or other documents of authorization (if any) must be delivered to the address of the Company’s office (for holders of A shares) or the office address of the Company’s H share registrar, Hong Kong Registrars Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong (for holders of H shares) no less than 24 hours before the time appointed for the holding of the AGM or any adjournment thereof.
- (iii) Holders of H Shares who have lodged the First Form of Proxy with the Company should note that:
  - (a) If the Second Form of Proxy is lodged with the office of the Company’s H Share Registrar 24 hours prior to the time designated for convening the AGM (the “Closing Time”), the Second Form of Proxy will revoke and supersede the First Form of Proxy previously lodged by him/her. The Second Form of Proxy will be treated as a valid form of proxy lodged by the holder of H Share(s) if correctly completed and signed and returned in accordance with the instructions printed thereon.

---

## SUPPLEMENTAL NOTICE OF THE AGM

---

- (b) If no Second Form of Proxy is lodged with the office of the Company's H Share registrar as at the Closing Time, the First Form of Proxy will be treated as a valid form of proxy lodged by the holder of H Share(s) if correctly completed. The proxy so appointed by the holder of H Share(s) will be entitled to vote at his/her discretion or to abstain from voting on any resolution properly put to the AGM including the resolution in relation to the proposed election of executive director as set out in the Supplemental Notice.
- (c) Completion and return of the First Form of Proxy and/or the Second Form of Proxy applicable to the AGM will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish. In such event, the appointment of the original proxy(ies) will be void.
6. To attend the AGM, an individual shareholder should bring along his/her identity card, shareholder account card; a proxy should bring along the proxy form, his/her identity card and the identity card of the principal and the shareholder account card for registration purpose. A legal person shareholder should bring along a copy of the business license, the proxy form signed by the legal entity, the shareholder account card and the identity card of the attendee for registration purpose.
7. Place and time of registration
- |                             |  |
|-----------------------------|--|
| Registration date and time: | 09:30 a.m.-11:30 a.m. and 2:30 p.m.-4:30 p.m. on 6 June 2019<br>(Thursday)   |
| Place of registration:      | Office of the secretariat to the Board, 2nd Floor, 45 Sha Mian North Street, Liwan District, Guangzhou City, Guangdong Province, the PRC |
8. Address:
- |                  |  |
|------------------|--|
| Postal code:     | 2nd Floor of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, 45 Sha Mian North Street, Liwan District, Guangzhou City, Guangdong Province, the PRC<br>510130 |
| Contact persons: | Huang Ruimei/Tan Yanli   |
| Telephone:       | (8620) 6628 1217/6628 1220   |
| Fax:             | (8620) 6628 1229   |
| Email:           | sec@gybys.com.cn   |
- |   |  |
|---|--|
| Address of Shanghai Branch Company of China Securities Depository and Clearing Corporation Limited: | 3/F., China Insurance Building, No. 166 Lujiazui Road East, Shanghai, the PRC      |
| Address of Hong Kong Registrars Limited:  | Shops 1712-1716, 17/F, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong |
9. The AGM is expected to last for a day. Shareholders attending the AGM shall be responsible for their own travelling and accommodation expenses.
10. Reporters attending the AGM shall register before the registration time for the shareholders.

*As at the date of this supplemental notice, the Board of the Company comprises Mr. Li Chuyuan, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Ni Yidong, Mr. Li Hong and Mr. Wu Changhai as executive directors, and Mr. Chu Xiaoping, Mr. Jiang Wenqi, Mr. Wong Hin Wing and Ms. Wang Weihong as independent non-executive directors.*